Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer |
| |
| Authors: | Yu-Yun Shao Wen-Yi Shau Zhong-Zhe Lin Ho-Min Chen Raymond Kuo James Chih-Hsin Yang Mei-Shu Lai |
| |
| Institution: | 1. Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan S Rd., Taipei 10002, Taiwan;2. Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, 7, Chung-Shan S Rd., Taipei 10002, Taiwan;3. Graduate Institute of Oncology, College of Medicine, National Taiwan University, 1, Sec. 1, Ren’ai Rd., Taipei City 10051, Taiwan;4. Cancer Research Center, College of Medicine, National Taiwan University, 1, Sec. 1, Ren’ai Rd., Taipei City 10051, Taiwan;5. Department of Internal Medicine, College of Medicine, National Taiwan University, 1, Sec. 1, Ren’ai Rd., Taipei City 10051, Taiwan;6. Division of Health Technology Assessment, Center For Drug Evaluation, 3F, No. 465, Sec. 6, Zhongxiao E. Rd., Taipei 11557, Taiwan;7. Department of Oncology, National Taiwan University Hospital, Yun-Lin Branch, 95, Xuefu Rd., Huwei Township, Yunlin County 63252, Yunlin, Taiwan;8. Taiwan Cancer Registry, P.O. Box 84-310 Taipei, Taipei City 10099, Taiwan;9. Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, No. 17, Xuzhou Rd., Taipei 10055, Taiwan |
| |
| Abstract: | PurposeThe epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the present study was to compare their efficacies in this population.Patients and methodsThe Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. Overall survival (OS) and time to treatment failure (TTF) were determined from registered parameters. Treatment efficacies were compared by the log-rank test in total population and subsets with different clinical characteristics. The Cox’s proportion hazard model was used to estimate the adjusted hazard ratios in multivariate analyses.ResultsA total of 984 patients who received gefitinib (67%) or erlotinib (33%) were included. Patients receiving gefitinib or erlotinib had similar OS (median, 10.2 versus 9.9 months, p = 0.524) and TTF (median, 5.5 versus 3.4 months, p = 0.103). In multivariate analyses, both treatment groups had similar risk of overall mortality (adjusted hazard ratio HR] = 1.04, p = 0.629) and treatment failure (adjusted HR = 0.94, p = 0.417). Comparing the treatments in subgroups based on age, tumour histology and gender also revealed no differences in OS and TTF. For patients who received gefitinib or erlotinib for more than 3 or 6 months, there was no difference in TTF but patients who received erlotinib had longer OS.ConclusionsGefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
